GRÁFICO.

Que sucede con el cancer actualmente? En el mejor de los casos muchos se curan, muchos desaparecen … y al cabo de 5-10 años vuelven. Por que? Porque aunque se liquidan las celulas cancerigenas ( matando a las sanas por el camino, ya sabemos todos lo dura que es la quimioterapia ), las pocas celulas que viven en estado de hipoxia no son aniquiladas y permanecen en el organismo, con el unico objetivo de un dia volver a resurigir y reaparecer, con el paso del tiempo esparcidas aun mas por el organismo y en metastasis. TH-302, basicamente, erradicaria esa posibilidad enormemente, por eso se le ha catalogado en algunos circulos como uno de los mayores logros para erradicar definitivamente el cancer.
Y , lo mejor, ataca selectivamente a las celulas cancerígenas en estado de hipoxia, pero no toca las sanas.

Dejo aqui una nota de los ultimos analistas en valorar precio objetivo de 12$:

H.C. Wainwright Reiterates Buy On Threshold Pharmaceuticals
Precio objetivo 12$

In a research note released yesterday, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $12 price target which represents a 264% upside from where the stock is currently trading.
Fein wrote, “Although the sarcoma program is scheduled to take a first shot at clinical and commercial success (data in 1Q16), it is the close-following pancreatic cancer program (data later in 2016) that unlocks greater value ($250M vs. $1.5B), while also in our view having even higher probability of success. Importantly, while THLD and its partner Merck continue to invest on the wide potential of TH-302 beyond STS and PC, we believe that the current trading levels of THLD shares offer a discount even to a base scenario of success consisting of: (1) launch of TH-302 in the STS and PC indications only; (2) conservative probability of success (60% for STS, 75% for PC); and (3) commercialization of TH-302 by Merck KGaA and revenues to THLD based on a royalty model only. Success in STS and/or PC, expansion into additional indications (such as NSCLC, GBM, or MM), and election by THLD to exercise its option to co-commercialize TH-302 with Merck KGaA in the US, would provide significant upside to our estimates and price target.“

——————————

Cantor Fitzgerald Reaffirms Buy On Threshold Pharmaceuticals Following Strong GBM Data
reitera precio objetivo 14$

In a research note released today, Cantor Fitzgerald analyst Daniel Brims reaffirmed a Buy rating on Threshold Pharmaceuticals (NASDAQ:THLD) with a $14 price target, following the company’s release of glioblastoma data, which has continued to demonstrate TH302’s efficacy.
Brims wrote, “We believe these results compared favorably with historical PFS and OS of ~1 month and 3 months respectively, strengthening our confidence that TH-302 can fill an unmet need in GBM and has efficacy in solid tumors.”
The analyst continued, “Dr. Brenner has received a grant from the FDA’s Office of Orphan Product Development in order to conduct a phase 3 trial of TH-302 and bevacizumab in 33 bevacizumab failure patients. Dr. Brenner’s grant is only one of 15 awarded this year by the FDA, demonstrating the significant unmet medical need in this patient population and the compelling nature of the phase 1/2 data collected to date. Historically, phase 2 data has been sufficient to gain regulatory approval and, while it is still unclear what endpoints FDA would accept (overall response rate, overall survival, or quality of life) for review, we expect this study, which could initiate as early as YE:14, to support an NDA filing»

Me he leído todos los post del Super pero necesito información adicional:

No estoy puesto en resultados contra el cancer y necesito saber que resultados son «un gran exito» en comparación con lo habitual.

Pero porque pienso en 2,90-3$??
Porque el Viernes es día de vencimiento de opciones y aunque THLD no se juega nada especial con ellas, los precios suelen erosionarse las semanas de vencimientos de opciones.

A saber …

¡Suerte!.

p.d.: Voy a tener que actualizar a esta pájara de nuevo

Framus después del barrido a 3,25 estoy mosqueado..hay otro pequeño gap en 3,19-3,21…si toca este, ya no te espero,aunque los indices están jodidos hoy, a menos que repunte….

Pero vete tu a saber …